The IL-6 and COX-2 expression related to sensitivity of chemoradiotherapy and prognosis in esophageal carcinoma

Japanese Journal of Cancer and Chemotherapy

Volumn 36, Issue 12, 2009, Pages 1979-1981

  Okamura, Shinichi ^a   Fujiwara, Hitoshi ^a   Suchi, Kentaro ^a   Okamura, Hiroko ^a   Umehara, Seiji ^a   Todo, Momoko ^a   Kuriu, Yoshiaki ^a   Ikoma, Hisashi ^a   Kubota, Takeshi ^a   Nakanishi, Masayoshi ^a   Ichikawa, Daisuke ^a   Kikuchi, Shojiro ^a   Okamoto, Kazuma ^a   Ochiai, Toshiya ^a   Sakakura, Chouhei ^a   Kokuba, Yukihito ^a   Sonoyama, Teruhisa ^a   Otsuji, Eigo ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Advanced esophageal cancer; Chemoradiation; COX 2; IL 6

Indexed keywords

INTERLEUKIN 6;

CANCER CELL; CHEMORADIOTHERAPY; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; HUMAN; INFLAMMATION; INFLAMMATORY CELL; NEOPLASM; OVERALL SURVIVAL; PATIENT; PROGNOSIS; SQUAMOUS CELL; STAINING; STROMA CELL; SURGERY; THERAPY; TISSUES;

EID: 84864614743     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Oka M, Yamamoto K, Takahashi M, et al: Relationship between serum levels of interleukin 6, various disease parameters, and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res 56(12): 2776-2780. 1996.
2. Wang LS, Chow KC and Wu CW: Expression and up-regulation of interleukin-6 in oesophageal carcinoma cells by n-sodium butyrate. Br J Cancer 80(10): 1617-1622, 1999.
3. Kalluri R and Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer 6(5): 392-401, 2006.
4. Mueller MM and Fusenig NE: Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4(11): 839-849, 2004.
5. Maihofner C, Charalambous MP, Bhambra U, et al: Expression of cyclooxygenase-2 parallels expression of in-terleukin-lbeta, interleukin-6 and NF-kappaB in human colorectal cancer. Carcinogenesis 24(4): 665-671, 2003.
6. CRP. Biotherapy 23(2): 113-118, 2009.
7. Kuo KT, Chow KC, Wu YC, et al: Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma. Ann Thorac Surg 76 (3): 909-914, 2003.
8. Nozoe T, Ezaki T, Kabashima A, et al: Significance of immunohistochemical expression of cyclooxygenase-2 in squamous cell carcinoma of the esophagus. Am J Surg 189(1): 110-115, 2005.
9. Xi H, Baldus SE, Warnecke-Eberz U, et al: High cyclooxygenase-2 expression following neoadjuvant radio-chemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin Cancer Res 11 (23): 8341-8347, 2005.
10. Huang WZ, Fu JH, Wang DK, et al: Overexpression of cyclooxygenase-2 is associated with chemoradiotherapy resistance and prognosis in esophageal squamous cell carcinoma patients. Dis Esophagus 21 (8): 679-684, 2008.
11. Wang LS, Chow KC and Wu YC: Effects of platelet activating factor, butyrate and interleukin-6 on cyclooxygenase-2 expression in human esophageal cancer cells. Scand J Gastroenterol 37 (4): 467-475, 2002.
12. Fosslien E: Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 30(1): 3-21, 2000.
13. Hussain SP and Harris CC: Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 121 (11): 2373-2380, 2007.
14. Leu CM, Wong FH, Chang C, et al: Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene 22 (49): 7809-7818. 2003.
15. Gallucci RM, Lee EG and Tomasek JJ: IL-6 modulates alpha-smooth muscle actin expression in dermal fibroblasts from IL-6-deficient mice. J Invest Dermatol 126(3): 561-568, 2006.